



ASX ANNOUNCEMENT

20 October 2026

Vitrafy appoints Jan Gielen as Chief Financial Officer

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **the Company**), a medical device Company that has designed and developed an innovative solution for the advancement of cryopreservation, today announces the appointment of Mr Jan Gielen as Chief Financial Officer (CFO). Jan is expected to commence in the role on 1 February 2027.

Jan brings more than 20 years of finance experience across ASX-listed and private businesses, including medical technology, healthcare, SaaS and high-growth private and private-equity backed businesses.

Most recently, he served as CFO of PolyNovo Limited (ASX: PNV), which he joined in December 2018 as it transitioned from an R&D-focused organisation to a commercial medical-device company. He supported the business through growth in revenue, manufacturing capability, international operations and investor engagement.

Jan will succeed current CFO Mr Simon Martin. The Vitrafy Board thanks Simon for his dedication and contribution to the Company and are pleased that he has agreed to continue to support management for a period of 6 months with an option for the Company to extend for a further 6 months if required.

Brent Owens, Chief Executive Officer, commented: "Jan's experience supporting the growth of an ASX listed medical technology business will be invaluable as Vitrafy expands its international operations. We thank Simon for his contribution as CFO and look forward to his ongoing contribution to Vitrafy."

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Adrian Mulcahy
Automic Markets
investors@vitrafy.com



About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware (the Guardion) and LifeChain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).